Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure | Zendy

Alexandre Mebazaa | Zendy; Theodore E. Spiro | Zendy; Harry R. Büller | Zendy; Lloyd Haskell | Zendy; Dayi Hu | Zendy; Russell D. Hull | Zendy; Geno J. Merli | Zendy; Sebastian Schellong | Zendy; Alex C. Spyropoulos | Zendy; Victor F. Tapson | Zendy; Yoriko De Sanctis | Zendy; Alexander T. Cohen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure

Author(s) -

Alexandre Mebazaa,

Theodore E. Spiro,

Harry R. Büller,

Lloyd Haskell,

Dayi Hu,

Russell D. Hull,

Geno J. Merli,

Sebastian Schellong,

Alex C. Spyropoulos,

Victor F. Tapson,

Yoriko De Sanctis,

Alexander T. Cohen

Publication year - 2014

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.113.003126

Subject(s) - medicine , venous thromboembolism , heart failure , intensive care medicine , cardiology , thrombosis

Whether heart failure (HF) increases the risk of venous thromboembolism (VTE) is not well established. In the phase III MAGELLAN (Multicenter, rAndomized, parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin) trial, extended-duration rivaroxaban was compared with standard-duration enoxaparin followed by placebo for VTE prevention in 8101 hospitalized acutely ill patients with or without HF. The aim of this analysis was to evaluate the relationship between HF severity and the risk of VTE in MAGELLAN patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research